Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Immune checkpoint inhibitor responses in KIT-mutated metastatic melanoma.
Authors
Meredith Ann McKean
The University of Texas MD Anderson Cancer Center, Houston, TX
Meredith Ann McKean, Junna Oba, Junsheng Ma, Lauren Elaine Haydu, Roland L. Bassett, Scott Eric Woodman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 199)
DOI
10.1200/JCO.2018.36.5_suppl.199
Abstract #
199
Poster Bd #
K8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2020 ASCO Virtual Scientific Program
Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1 inhibitors in metastatic NSCLC.
First Author: Sally CM Lau
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2022 ASCO Annual Meeting
Assessment of a 4-chemokine signature in prediction of T-cell inflammation and response to immune checkpoint inhibition across tumor types.
First Author: Joan Miguel Romero